PMID- 32945369
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210908
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 57
IP  - 4
DP  - 2020 Oct
TI  - Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the 
      induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells.
PG  - 1047-1056
LID - 10.3892/ijo.2020.5110 [doi]
AB  - The proliferation and activation of CD4+ T helper 1 (Th1) cells and CD8+ 
      cytotoxic T lymphocytes (CTLs) that produce interferon‑gamma (IFN‑gamma) is an essential 
      action of effective cancer vaccines. Recently, a novel Wilms' tumor 1 (WT1) 
      helper peptide (WT1 HP34‑51; amino acid sequence, WAPVLDFAPPGASAYGSL) applicable 
      for various human leukocyte antigen (HLA) subtypes (HLA‑DR, HLA‑DP and HLA‑DQ) 
      was reported to increase peptide immunogenicity; however, the function of WT1 
      HP34‑51 remains unclear. In the present study, mature dendritic cells (mDCs) 
      pulsed with WT1 HP34‑51 (mDC/WT1 HP34‑51) activated not only WT1‑specific CD4+ T 
      cells but also CD8+ T cells that produced IFN‑gamma following stimulation with 
      immature dendritic cells (imDCs) pulsed with WT1 killer peptide (imDC/WT1 
      KP37‑45) in an HLA‑A*02:01‑ or HLA‑A*02:06‑restricted manner. Furthermore, the 
      activated WT1‑reactive CD4+ Th1 cells were predominantly effector memory (EM) T 
      cells. In 5 of 12 (41.7%) patients with cancer carrying the HLA‑A*02:01 or 
      HLA‑A*02:06 allele, WT1‑reactive CD8+ T cells stimulated with mDC/WT1 HP34‑51 
      enhanced their levels of WT1 KP37‑45‑specific IFN‑gamma production, with an increase 
      >10%. Simultaneous activation of CD4+ and CD8+ T cells occurred more often when 
      stimulation with mDC/WT1 HP34‑51 was combined with imDC/WT1 KP37‑45 
      restimulation. These results indicated that the novel mDC/WT1 HP34‑51 combination 
      induced responses by WT1‑specific EM CD4+ Th1 cells and HLA‑A*02:01‑ or 
      HLA‑A*02:06‑restricted CD8+ CTLs, suggesting its potential as a WT1‑targeting 
      cancer vaccine.
FAU - Kan, Shin
AU  - Kan S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Kashiwa Hospital, Kashiwa, Chiba 277‑8567, 
      Japan.
FAU - Bito, Tsuuse
AU  - Bito T
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Kashiwa Hospital, Kashiwa, Chiba 277‑8567, 
      Japan.
FAU - Shimabuku, Masamori
AU  - Shimabuku M
AD  - Tokyo Midtown Center for Advanced Medical Science and Technology, Tokyo 107‑6206, 
      Japan.
FAU - Taguchi, Junichi
AU  - Taguchi J
AD  - Tokyo Midtown Center for Advanced Medical Science and Technology, Tokyo 107‑6206, 
      Japan.
FAU - Ohkusa, Toshifumi
AU  - Ohkusa T
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Kashiwa Hospital, Kashiwa, Chiba 277‑8567, 
      Japan.
FAU - Shimodaira, Shigetaka
AU  - Shimodaira S
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Ishikawa 
      920‑0293, Japan.
FAU - Sugiyama, Haruo
AU  - Sugiyama H
AD  - Department of Functional Diagnostic Science, Osaka University Graduate School of 
      Medicine, Osaka 565‑0871, Japan.
FAU - Koido, Shigeo
AU  - Koido S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Kashiwa Hospital, Kashiwa, Chiba 277‑8567, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20200814
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Peptide Fragments)
RN  - 0 (WT1 Proteins)
RN  - 0 (WT1 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cells, Cultured
MH  - Dendritic Cells/drug effects/*immunology/transplantation
MH  - Female
MH  - HLA-A2 Antigen/*immunology
MH  - Humans
MH  - Immunotherapy, Adoptive/methods
MH  - Kidney Neoplasms/blood/immunology/*therapy
MH  - Leukocytes, Mononuclear
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*pharmacology
MH  - Th1 Cells/immunology
MH  - WT1 Proteins/*immunology
MH  - Wilms Tumor/blood/immunology/*therapy
OTO - NOTNLM
OT  - dendritic cell
OT  - Wilms' tumor 1
OT  - helper peptide
OT  - cytotoxic T lymphocytes
OT  - interferon-gamma
EDAT- 2020/09/19 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/09/18 08:43
PHST- 2020/03/15 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2020/09/18 08:43 [entrez]
AID - 10.3892/ijo.2020.5110 [doi]
PST - ppublish
SO  - Int J Oncol. 2020 Oct;57(4):1047-1056. doi: 10.3892/ijo.2020.5110. Epub 2020 Aug 
      14.